Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor

Several reports have indicated that the chemokine receptor CCR5 and its ligands, especially CCL5 (formerly known as RANTES), may play a role in the pathogenesis of psoriasis. The purpose of this investigation was to examine the expression of CCR5 and its ligands in chronic plaque psoriasis and to evaluate the clinical and immunohistochemical effect of a CCR5 receptor inhibitor. Immunohistochemical analysis showed low but significant increased total numbers of CCR5 positive cells in epidermis and dermis of lesional skin in comparison to non-lesional skin. However, relative expression of CCR5 proportional to the cells observed revealed that the difference between lesional and non-lesional skin was only statistically significant in the epidermis for CD3 positive cells and in the dermis for CD68 positive cells. Quantification of mRNA by reverse transcriptase-polymerase chain reaction only showed an increased expression of CCL5 (RANTES) in lesional skin. A randomized placebo-controlled clinical trial in 32 psoriasis patients revealed no significant clinical effect and no changes at the immunohistochemical level comparing patients treated with placebo or a CCR5 inhibitor SCH351125. We conclude that although CCR5 expression is increased in psoriatic lesions, this receptor does not play a crucial role in the pathogenesis of psoriasis.

[1]  C. Mackay,et al.  The role of chemokine receptors in primary, effector, and memory immune responses. , 2000, Annual review of immunology.

[2]  S. Porcelli,et al.  Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. , 2000, Journal of dermatological science.

[3]  James J. Campbell,et al.  Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. , 2002, The American journal of pathology.

[4]  A. Gottlieb,et al.  Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. , 1992, The Journal of investigative dermatology.

[5]  J. Schröder,et al.  Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. , 1986, The Journal of investigative dermatology.

[6]  Sato,et al.  RANTES expression in psoriatic skin, and regulation of RANTES and IL‐8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol) , 1998, The British journal of dermatology.

[7]  H. Nomiyama,et al.  Chemokines in immunity. , 2001, Advances in immunology.

[8]  J. Barker,et al.  Pathophysiology of psoriasis. , 1977, Annual review of medicine.

[9]  L. Austin,et al.  CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. , 2000, Journal of autoimmunity.

[10]  S. Porcelli,et al.  Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. , 1999, Archives of dermatology.

[11]  A. Bowcock,et al.  Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.

[12]  S. Porcelli,et al.  Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN-γ Production by NK-T Cells1 , 2000, The Journal of Immunology.

[13]  J. Bos,et al.  T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-γ expression , 2004, Archives of Dermatological Research.

[14]  S. Narula,et al.  Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. , 2005, Arthritis and rheumatism.

[15]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[16]  M. Baggiolini,et al.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes , 1996, The Journal of experimental medicine.

[17]  Eric J Kunkel,et al.  Chemokines and the tissue-specific migration of lymphocytes. , 2002, Immunity.

[18]  James G Krueger,et al.  Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin αEβ7 in the Pathogenesis of Psoriasis Vulgaris , 2001, Laboratory Investigation.

[19]  A. Giannetti,et al.  Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. , 2001, The Journal of allergy and clinical immunology.

[20]  M. Sticherling,et al.  The CXC receptor 2 is overexpressed in psoriatic epidermis. , 1998, The Journal of investigative dermatology.

[21]  H. Valdimarsson,et al.  The effects of cyclosporin A on T lymphocyte and dendritic cell sub‐populations in psoriasis , 1987, The British journal of dermatology.

[22]  James G. Krueger,et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis , 1995, Nature Genetics.

[23]  H. Suto,et al.  Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis. , 2002, International immunology.

[24]  A. Trkola,et al.  The Differential Sensitivity of Human and Rhesus Macaque CCR5 to Small-Molecule Inhibitors of Human Immunodeficiency Virus Type 1 Entry Is Explained by a Single Amino Acid Difference and Suggests a Mechanism of Action for These Inhibitors , 2004, Journal of Virology.

[25]  C. Pert,et al.  Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. , 1999, Acta dermato-venereologica.

[26]  G. Krueger,et al.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.

[27]  J. Voorhees,et al.  Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. , 1995, The Journal of investigative dermatology.

[28]  C. Griffiths,et al.  Natural killer and natural killer-T cells in psoriasis , 2002, Archives of Dermatological Research.

[29]  G. Girolomoni,et al.  CD56brightCD16– NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation , 2006, European journal of immunology.

[30]  William J Greenlee,et al.  Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist. , 2003, Bioorganic & medicinal chemistry letters.

[31]  J G Krueger,et al.  Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. , 2001, Laboratory investigation; a journal of technical methods and pathology.

[32]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[33]  B. Gesser,et al.  Expression of the T‐helper 2‐specific chemokine receptor CCR4 on CCR10‐positive lymphocytes in atopic dermatitis skin but not in psoriasis skin , 2003, The British journal of dermatology.

[34]  A. L. Cameron,et al.  Circulating natural killer cells in psoriasis , 2003, The British journal of dermatology.

[35]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[36]  M. Mack,et al.  Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease , 2003, Nature Medicine.

[37]  Serena Xu,et al.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Bröcker,et al.  Differential Expression of GRO-α and IL-8 mRNA Psoriasis: A Model for Neutrophil Migration and Accumulation In Vivo , 1996 .

[39]  J. Travers,et al.  Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. , 2003, The Journal of allergy and clinical immunology.

[40]  J. Bos,et al.  Immunocompetent cells in psoriasis , 1983, Archives of Dermatological Research.

[41]  C. Caux,et al.  Up-Regulation of Macrophage Inflammatory Protein-3α/CCL20 and CC Chemokine Receptor 6 in Psoriasis1 , 2000, The Journal of Immunology.

[42]  M. Baggiolini,et al.  Chemokines and their receptors in lymphocyte traffic and HIV infection. , 2000, Advances in immunology.

[43]  M. Baggiolini,et al.  CCR5 is characteristic of Th1 lymphocytes , 1998, Nature.

[44]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[45]  C. Murdoch,et al.  Chemokine receptors and their role in inflammation and infectious diseases. , 2000, Blood.

[46]  I. Flisiak,et al.  Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[47]  P. Allavena,et al.  Chemokines and Dendritic Cell Traffic , 2000, Journal of Clinical Immunology.

[48]  F. Nestle,et al.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. , 2004, The Journal of clinical investigation.

[49]  H. Brühl,et al.  Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice1 , 2001, The Journal of Immunology.

[50]  M. D. de Rie,et al.  Psoriasis: dysregulation of innate immunity , 2005, The British journal of dermatology.

[51]  P. Tak,et al.  Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis , 2005, Archives of Dermatological Research.

[52]  Marketa Zvelebil,et al.  Phosphoinositide 3-kinase signalling--which way to target? , 2003, Trends in pharmacological sciences.

[53]  J. Flier,et al.  Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation , 2001, The Journal of pathology.

[54]  M. Schön,et al.  Animal models of psoriasis - what can we learn from them? , 1999, The Journal of investigative dermatology.

[55]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[56]  M. Thelen,et al.  Dancing to the tune of chemokines , 2001, Nature Immunology.

[57]  M. Amicosante,et al.  Expression of CCR5 is increased in human monocyte-derived macrophages and alveolar macrophages in the course of in vivo and in vitro Mycobacterium tuberculosis infection. , 1999, AIDS research and human retroviruses.

[58]  E. Bröcker,et al.  Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. , 1996, The Journal of investigative dermatology.

[59]  J. Esté.  Sch-351125 and Sch-350634. Schering-Plough. , 2002, Current opinion in investigational drugs.